AstraZeneca’s in vivo CAR-T led to early responses, but one death in China trial

Lei Lei Wu / endpoints - New clinical trial data on the in vivo CAR-T therapy that AstraZeneca acquired last year suggest that while the experimental treatment can curb multiple myeloma in some patients, it may not be safer than the ...

AI Summary: Early reports from a phase 1 in‑vivo CAR‑T program show promising anti‑myeloma activity following direct in‑body CAR induction targeting BCMA, but investigators also reported a treatment‑related death in a China trial. The mixed signals underscore the potential of in‑vivo CAR approaches while spotlighting safety, dosing and monitoring challenges that must be resolved before wider adoption.

• AstraZeneca's in‑vivo CAR‑T: early wins, serious safety questions (4)
• Myeloma community reacts: experts, conferences and paper highlights (7)
• Next‑gen T‑cell strategies and regulatory hurdles (4)
• All Other Stories

AstraZeneca's in‑vivo CAR‑T: early wins, serious safety questions

Myeloma community reacts: experts, conferences and paper highlights

Next‑gen T‑cell strategies and regulatory hurdles

All Other Stories